Kaempferol inhibits fibroblast collagen synthesis, proliferation and activation in hypertrophic scar via targeting TGF-β receptor type I

Biomedicine and Pharmacotherapy

Volumn 83, Issue , 2016, Pages 967-974

  Li, Hongwei ^a   Yang, Liu ^b   Zhang, Yuebing ^c   Gao, Zhigang ^c  

^a Zhejiang Minzheng Rehabilitation Center   (China)

^b ZHEJIANG CHINESE MEDICAL UNIVERSITY   (China)

^c ZHEJIANG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

Fibroblasts; Hypertrophic scar; Kaempferol; TGF 1 Smads; TGF RI

Indexed keywords

COLLAGEN; COLLAGEN 1 ALPHA 2; COLLAGEN TYPE 1; COLLAGEN TYPE 3; COLLAGEN TYPE 3 ALPHA 1; KAEMPFEROL; SMAD2 PROTEIN; SMAD3 PROTEIN; TRANSFORMING GROWTH FACTOR BETA RECEPTOR 1; UNCLASSIFIED DRUG; KAEMPFEROL DERIVATIVE; SMAD PROTEIN; TRANSFORMING GROWTH FACTOR BETA RECEPTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BIOLOGICAL ACTIVITY; CELL ACTIVATION; CELL PROLIFERATION; COLLAGEN SYNTHESIS; CONTROLLED STUDY; DOWN REGULATION; DRUG RECEPTOR BINDING; FEMALE; FIBROBLAST CULTURE; HYPERTROPHIC SCAR; IN VITRO STUDY; IN VIVO STUDY; INTRACELLULAR SIGNALING; INTRADERMAL DRUG ADMINISTRATION; MALE; MOUSE; MOUSE MODEL; NONHUMAN; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; SKIN; SKIN FIBROBLAST; WESTERN BLOTTING; ADULT; ANIMAL; APOPTOSIS; BAGG ALBINO MOUSE; BIOSYNTHESIS; DRUG EFFECTS; FIBROBLAST; HUMAN; METABOLISM; PATHOLOGY; SIGNAL TRANSDUCTION; YOUNG ADULT;

ADULT; ANIMALS; APOPTOSIS; CELL PROLIFERATION; CICATRIX, HYPERTROPHIC; COLLAGEN; DOWN-REGULATION; FEMALE; FIBROBLASTS; HUMANS; KAEMPFEROLS; MALE; MICE, INBRED BALB C; RECEPTORS, TRANSFORMING GROWTH FACTOR BETA; SIGNAL TRANSDUCTION; SMAD PROTEINS; YOUNG ADULT;

EID: 84981341012     PISSN: 07533322     EISSN: 19506007     Source Type: Journal    
DOI: 10.1016/j.biopha.2016.08.011     Document Type: Article

References (45)

1. [1] Zhao, J., Shu, B., Chen, L., Tang, J., Zhang, L., Xie, J., Liu, X., Xu, Y., Qi, S., Prostaglandin E inhibits collagen synthesis in dermal fibroblasts and prevents hypertrophic scar formation in vivo. Exp. Dermatol. 25:8 (2016), 604–610.
2. [2] Ledon, J.A., Savas, J., Franca, K., Chacon, A., Nouri, K., Intralesional treatment for keloids and hypertrophic scars: a review. Dermatol. Surg. 39:12 (2013), 1745–1757.
3. [3] Zielins, E.R., Atashroo, D.A., Maan, Z.N., Duscher, D., Walmsley, G.G., Hu, M., Senarath-Yapa, K., McArdle, A., Tevlin, R., Wearda, T., Paik, K.J., Duldulao, C., Hong, W.X., Gurtner, G.C., Longaker, M.T., Wound healing: an update. Regen. Med. 9:6 (2014), 817–830.
4. [4] Niessen, F.B., Spauwen, P.H., Schalkwijk, J., Kon, M., On the nature of hypertrophic scars and keloids: a review. Plast. Reconstr. Surg. 104:5 (1999), 1435–1458.
5. [5] Zhang, H., Ran, X., Hu, C.L., Qin, L.P., Lu, Y., Peng, C., Therapeutic effects of liposome-enveloped Ligusticum chuanxiong essential oil on hypertrophic scars in the rabbit ear model. PLoS One, 7(2), 2012, e31157.
6. [6] Xiao, Y.Y., Fan, P.J., Lei, S.R., Qi, M., Yang, X.H., MiR-138/peroxisome proliferator-activated receptor beta signaling regulates human hypertrophic scar fibroblast proliferation and movement in vitro. J. Dermatol. 42:5 (2015), 485–495.
7. [7] Mukhopadhyay, A., Do, D.V., Ong, C.T., Khoo, Y.T., Masilamani, J., Chan, S.Y., Vincent, A.S., Wong, P.K., Lim, C.P., Cao, X., Lim, I.J., Phan, T.T., The role of stem cell factor and c-KIT in keloid pathogenesis: do tyrosine kinase inhibitors have a potential therapeutic role?. Br. J. Dermatol. 164:2 (2011), 372–386.
8. [8] Bayat, A., McGrouther, D.A., Ferguson, M.W., Skin scarring. BMJ 326:7380 (2003), 88–92.
9. [9] Sarrazy, V., Billet, F., Micallef, L., Coulomb, B., Desmouliere, A., Mechanisms of pathological scarring: role of myofibroblasts and current developments. Wound Repair. Regen. 19:Suppl. 1 (2011), s10–s15.
10. [10] Khedgikar, V., Kushwaha, P., Gautam, J., Sharma, S., Verma, A., Choudhary, D., Mishra, P.R., Trivedi, R., Kaempferol targets Krt-14 and induces cytoskeletal mineralization in osteoblasts: a mechanistic approach. Life Sci. 151 (2016), 207–217.
11. [11] Devi, K.P., Malar, D.S., Nabavi, S.F., Sureda, A., Xiao, J., Nabavi, S.M., Daglia, M., Kaempferol and inflammation: from chemistry to medicine. Pharmacol. Res. 99 (2015), 1–10.
12. [12] Zhou, M., Ren, H., Han, J., Wang, W., Zheng, Q., Wang, D., Protective effects of kaempferol against myocardial ischemia/reperfusion injury in isolated rat heart via antioxidant activity and inhibition of glycogen synthase kinase-3beta. Oxid. Med. Cell Longev., 2015, 2015, 481405.
13. [13] Lee, C.F., Yang, J.S., Tsai, F.J., Chiang, N.N., Lu, C.C., Huang, Y.S., Chen, C., Chen, F.A., Kaempferol induces ATM/p53-mediated death receptor and mitochondrial apoptosis in human umbilical vein endothelial cells. Int. J. Oncol. 48:5 (2016), 2007–2014.
14. [14] Luo, C., Yang, H., Tang, C., Yao, G., Kong, L., He, H., Zhou, Y., Kaempferol alleviates insulin resistance via hepatic IKK/NF-kappaB signal in type 2 diabetic rats. Int. Immunopharmacol. 28:1 (2015), 744–750.
15. [15] Kim, M., Lim, S.J., Kang, S.W., Um, B.H., Nho, C.W., Aceriphyllum rossii extract and its active compounds, quercetin and kaempferol inhibit IgE-mediated mast cell activation and passive cutaneous anaphylaxis. J. Agric. Food Chem. 62:17 (2014), 3750–3758.
16. [16] Maini, S., Fahlman, B.M., Krol, E.S., Flavonols protect against UV radiation-induced thymine dimer formation in an artificial skin mimic. J. Pharm. Pharm. Sci. 18:4 (2015), 600–615.
17. [17] Berman, B., Maderal, A., Raphael, B., Keloids and hypertrophic scars: pathophysiology, classification, and treatment. Dermatol. Surg., 2016.
18. [18] Saulis, A.S., Mogford, J.H., Mustoe, T.A., Effect of Mederma on hypertrophic scarring in the rabbit ear model. Plast. Reconstr. Surg. 110:1 (2002), 177–183.
19. [19] Koc, E., Arca, E., Surucu, B., Kurumlu, Z., An open, randomized, controlled, comparative study of the combined effect of intralesional triamcinolone acetonide and onion extract gel and intralesional triamcinolone acetonide alone in the treatment of hypertrophic scars and keloids. Dermatol. Surg. 34:11 (2008), 1507–1514.
20. [20] Phan, T.T., Sun, L., Bay, B.H., Chan, S.Y., Lee, S.T., Dietary compounds inhibit proliferation and contraction of keloid and hypertrophic scar-derived fibroblasts in vitro: therapeutic implication for excessive scarring. J. Trauma. 54:6 (2003), 1212–1224.
21. [21] Aarabi, S., Bhatt, K.A., Shi, Y., Paterno, J., Chang, E.I., Loh, S.A., Holmes, J.W., Longaker, M.T., Yee, H., Gurtner, G.C., Mechanical load initiates hypertrophic scar formation through decreased cellular apoptosis. FASEB J. 21:12 (2007), 3250–3261.
22. [22] Salic, A., Mitchison, T.J., A chemical method for fast and sensitive detection of DNA synthesis in vivo. Proc. Natl. Acad. Sci. U. S. A. 105:7 (2008), 2415–2420.
23. [23] Lebakken, C.S., Riddle, S.M., Singh, U., Frazee, W.J., Eliason, H.C., Gao, Y., Reichling, L.J., Marks, B.D., Vogel, K.W., Development and applications of a broad-coverage, TR-FRET-based kinase binding assay platform. J. Biomol. Screen. 14:8 (2009), 924–935.
24. [24] Zhang, Y., Shan, S., Wang, J., Cheng, X., Yi, B., Zhou, J., Li, Q., Galangin inhibits hypertrophic scar formation via ALK5/Smad2/3 signaling pathway. Mol. Cell. Biochem. 413:1–2 (2016), 109–118.
25. [25] Wang, J., Zhou, J., Zhang, N., Zhang, X., Li, Q., A heterocyclic molecule kartogenin induces collagen synthesis of human dermal fibroblasts by activating the smad4/smad5 pathway. Biochem. Biophys. Res. Commun. 450:1 (2014), 568–574.
26. [26] Hinz, B., Formation and function of the myofibroblast during tissue repair. J. Invest. Dermatol. 127:3 (2007), 526–537.
27. [27] He, S., Liu, X., Yang, Y., Huang, W., Xu, S., Yang, S., Zhang, X., Roberts, M.S., Mechanisms of transforming growth factor beta(1)/Smad signalling mediated by mitogen-activated protein kinase pathways in keloid fibroblasts. Br. J. Dermatol. 162:3 (2010), 538–546.
28. [28] Hayashi, H., Abdollah, S., Qiu, Y., Cai, J., Xu, Y.Y., Grinnell, B.W., Richardson, M.A., Topper, J.N., Gimbrone, M.A. Jr., Wrana, J.L., Falb, D., The MAD-related protein Smad7 associates with the TGFbeta receptor and functions as an antagonist of TGFbeta signaling. Cell 89:7 (1997), 1165––1173.
29. [29] Arno, A.I., Gauglitz, G.G., Barret, J.P., Jeschke, M.G., Up-to-date approach to manage keloids and hypertrophic scars: a useful guide. Burns 40:7 (2014), 1255–1266.
30. [30] Ehrlich, H.P., Desmouliere, A., Diegelmann, R.F., Cohen, I.K., Compton, C.C., Garner, W.L., Kapanci, Y., Gabbiani, G., Morphological and immunochemical differences between keloid and hypertrophic scar. Am. J. Pathol. 145:1 (1994), 105–113.
31. [31] Leventhal, D., Furr, M., Reiter, D., Treatment of keloids and hypertrophic scars: a meta-analysis and review of the literature. Arch. Facial Plast. Surg. 8:6 (2006), 362–368.
32. [32] Vrijman, C., van Drooge, A.M., Limpens, J., Bos, J.D., van der Veen, J.P., Spuls, P.I., Wolkerstorfer, A., Laser and intense pulsed light therapy for the treatment of hypertrophic scars: a systematic review. Br. J. Dermatol. 165:5 (2011), 934–942.
33. [33] Anzarut, A., Olson, J., Singh, P., Rowe, B.H., Tredget, E.E., The effectiveness of pressure garment therapy for the prevention of abnormal scarring after burn injury: a meta-analysis. J. Plast. Reconstr. Aesthet. Surg. 62:1 (2009), 77–84.
34. [34] Macintyre, L., Baird, M., Pressure garments for use in the treatment of hypertrophic scars–a review of the problems associated with their use. Burns 32:1 (2006), 10–15.
35. [35] Reish, R.G., Eriksson, E., Scars: a review of emerging and currently available therapies. Plast. Reconstr. Surg. 122:4 (2008), 1068–1078.
36. [36] Honardoust, D., Kwan, P., Momtazi, M., Ding, J., Tredget, E.E., Novel methods for the investigation of human hypertrophic scarring and other dermal fibrosis. Methods Mol. Biol. 1037 (2013), 203–231.
37. [37] Moreels, M., Vandenabeele, F., Dumont, D., Robben, J., Lambrichts, I., Alpha-smooth muscle actin (alpha-SMA) and nestin expression in reactive astrocytes in multiple sclerosis lesions: potential regulatory role of transforming growth factor-beta 1 (TGF-beta1). Neuropathol. Appl. Neurobiol. 34:5 (2008), 532–546.
38. [38] Gong, J.H., Cho, I.H., Shin, D., Han, S.Y., Park, S.H., Kang, Y.H., Inhibition of airway epithelial-to-mesenchymal transition and fibrosis by kaempferol in endotoxin-induced epithelial cells and ovalbumin-sensitized mice. Lab. Invest. 94:3 (2014), 297–308.
39. [39] Gurtner, G.C., Werner, S., Barrandon, Y., Longaker, M.T., Wound repair and regeneration. Nature 453:7193 (2008), 314–321.
40. [40] Li, B., Gao, C., Diao, J.S., Wang, D.L., Chu, F.F., Li, Y., Wang, G., Guo, S.Z., Xia, W., Aberrant Notch signalling contributes to hypertrophic scar formation by modulating the phenotype of keratinocytes. Exp. Dermatol. 25:2 (2016), 137–142.
41. [41] Kang, B.Y., Kim, S., Lee, K.H., Lee, Y.S., Hong, I., Lee, M.O., Min, D., Chang, I., Hwang, J.S., Park, J.S., Kim, D.H., Kim, B.G., Transcriptional profiling in human HaCaT keratinocytes in response to kaempferol and identification of potential transcription factors for regulating differential gene expression. Exp. Mol. Med. 40:2 (2008), 208–219.
42. [42] Leask, A., Abraham, D.J., TGF-beta signaling and the fibrotic response. FASEB J. 18:7 (2004), 816–827.
43. [43] Li, J., Chen, K., Li, S., Feng, J., Liu, T., Wang, F., Zhang, R., Xu, S., Zhou, Y., Zhou, S., Xia, Y., Lu, J., Zhou, Y., Guo, C., Protective effect of fucoidan from Fucus vesiculosus on liver fibrosis via the TGF-beta1/Smad pathway-mediated inhibition of extracellular matrix and autophagy. Drug Des. Dev. Ther. 10 (2016), 619–630.
44. [44] Kim, S., Lim, J.H., Woo, C.H., ERK5 inhibition ameliorates pulmonary fibrosis via regulating Smad3 acetylation. Am. J. Pathol. 183:6 (2013), 1758–1768.
45. [45] Zhao, M., Zheng, S., Yang, J., Wu, Y., Ren, Y., Kong, X., Li, W., Xuan, J., Suppression of TGF-beta1/Smad signaling pathway by sesamin contributes to the attenuation of myocardial fibrosis in spontaneously hypertensive rats. PLoS One, 10(3), 2015, e0121312.